Clinical Trial Record

Return to Clinical Trials

Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer


2015-01-01


2024-12-31


2024-12-31


100

Study Overview

Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

N/A

  • Pancreatic Cancer Resectable
  • DRUG: gemcitabine
  • iON study

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2025-01-30  

N/A  

2025-01-30  

2025-01-30  

N/A  

2025-02-05  

2025-02-05  

N/A  

2025-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Primary Outcome MeasuresMeasure DescriptionTime Frame
Investigating the Presence of Occult Metastatic Lesions Detected During Neoadjuvant Therapy.within 6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:
1

    Inclusion Criteria:

  • radiologically resectable pancreatic cancer patients

  • Exclusion Criteria:

  • a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available